AECOM(ACM) - 2025 Q3 - Earnings Call Presentation
2025-08-05 12:00
Financial Performance - Net service revenue increased by 6% from $1826 million in Q3'24 to $1938 million in Q3'25[9] - Segment adjusted operating margin increased by 90 bps from 163% in Q3'24 to 171% in Q3'25[9] - Adjusted EPS increased by 16% from $116 in Q3'24 to $134 in Q3'25[9] - Total backlog increased by 5% from $23362 million in Q3'24 to $24588 million in Q3'25[9] - The company expects to convert 100% of adjusted net income to free cash flow in FY'25[17] Guidance and Strategic Accomplishments - Increased fiscal 2025 adjusted EBITDA guidance by 10% from $1170-$1210 million to $1190-$1210 million[10] - Increased fiscal 2025 adjusted EPS guidance by 16% from $500-$520 to $520-$530[10] - Industry-leading margins exceeded 17% target[13] - Returned nearly $240 million to shareholders in fiscal 2025 to date[13] Segment Performance - Americas net service revenue increased by 8%[21] with adjusted operating margin increasing by 120 bps to 205%[23] - International net service revenue increased by 3%[22] with adjusted operating margin increasing by 20 bps to 119%[23]
First Watch Restaurant (FWRG) - 2025 Q2 - Earnings Call Presentation
2025-08-05 12:00
Q2 2025 SUPPLEMENTAL INFORMATION August 5, 2025 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS AND NON-GAAP FINANCIAL MEASURES FORWARD LOOKING STATEMENTS In addition to historical information, this presentation may contain a number of "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, which are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different from the statements made herein. All ...
Leidos(LDOS) - 2025 Q2 - Earnings Call Presentation
2025-08-05 12:00
Leidos Q2 FY25 Earnings Conference Call AUGUST 5, 2025 FORWARD-LOOKING STATEMENTS Certain statements contain or are based on "forward-looking" information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "guidance" and similar words or phrases. Forward-looking statements include, among others, estimates of our future growth, strategy an ...
Shoals Technologies (SHLS) - 2025 Q2 - Earnings Call Presentation
2025-08-05 12:00
Q2 EARNINGS REPORT August 2025 © 2025 Shoals Technologies Group Disclaimer Forward-Looking Statements This presentation contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements include information concerning our possible or assumed future results of operations; expectations regarding the utility-scale solar market; project delays; regulatory environment; the effects of strategic pricing ...
AxoGen(AXGN) - 2025 Q2 - Earnings Call Presentation
2025-08-05 12:00
Financial Performance - Q2 2025 revenue increased to $56.7 million, representing an 18.3% year-over-year growth[12,22] - Q2 2025 gross margin was 74.2%, a 0.4% increase compared to 2024[24] - Net income for Q2 2025 was $0.6 million, compared to a loss of $1.9 million in Q2 2024[26] - Adjusted EBITDA for Q2 2025 was $9.3 million, compared to $5.6 million in Q2 2024[26] - Operational cash flow increased by $7.8 million, from $28.1 million on March 31, 2025, to $35.9 million on June 30, 2025[28] Business Growth & Development - High Potential (HiPo) accounts yielded approximately 70% of year-over-year revenue growth year-to-date[12] - HiPo accounts have yielded a 21% year-over-year increase in average account productivity year-to-date[12] - The company added approximately 10 million estimated additional covered lives in Q2 via BCBS policy changes, with approximately 17 million estimated new lives year-to-date[14] Guidance - The company raised its full-year 2025 revenue growth guidance to at least 17%, or $219 million[30]
Fresenius Medical Care AG(FMS) - 2025 Q2 - Earnings Call Presentation
2025-08-05 12:00
Financial Performance - Fresenius Medical Care achieved strong organic revenue growth of 7% in Q2 2025, supported by all operating segments[9] - Operating income grew by 13% at constant currency, driving margin expansion[9] - Operating cash flow improved significantly by 75%[9] - The net leverage ratio improved to 2.7x[9] - Q2 2025 revenue reached €4792 million, a 5% increase at constant currency and 0.5% as reported, with 6.7% organic growth[22] - Operating income excluding special items was €476 million, up 12.9% at constant currency and 9.2% at current rates[24] Segment Performance - Care Delivery revenue was €3381 million, with 3.4% organic growth in the U S and 4.5% internationally[31, 34] - Value-Based Care revenue increased to €506 million, a 28.4% increase at constant currency[36] - Care Enablement revenue reached €1348 million, with 3.4% organic growth[43] Cash Flow and Debt - Operating cash flow increased to €775 million in Q2 2025, a 75% improvement[48] - Free cash flow rose to €628 million, a 117% increase[48] - Total net debt and lease liabilities decreased to €9315 million[48] Outlook - Fresenius Medical Care confirmed its FY 2025 outlook, projecting positive to low-single digit percent revenue growth and high-teens to high-twenties percent operating income growth, both at constant currency and excluding special items[9, 55]
Gartner(IT) - 2025 Q2 - Earnings Call Presentation
2025-08-05 12:00
Q2 2025 Financial Performance - Consolidated revenues reached $1686 million, a 5.7% increase year-over-year, or 4.6% on a foreign exchange (FX) neutral basis[6] - Insights revenues grew by 4.2% to $1319 million, or 3.3% on an FX neutral basis, with a contribution margin of 73.9%[6] - Conference revenues increased by 13.6% to $211 million, or 12.0% on an FX neutral basis, boasting a contribution margin of 57.4%[6] - Consulting revenues rose by 8.8% to $156 million, or 6.5% on an FX neutral basis, with a contribution margin of 39.6%[6] - Adjusted EBITDA increased by 6.6% to $443 million, with an Adjusted EBITDA margin of 26.3%[6] - Adjusted EPS grew by 9.6% to $3.53[6] - Free cash flow was $347 million[6] Contract Value Growth - Global contract value (CV) increased by 4.9%[6] - Global Technology Sales CV grew by 3.6% to $3800 million[6] - Global Business Sales CV increased by 9.2% to $1200 million[6] Updated 2025 Guidance - The company projects consolidated revenues of at least $6455 billion[7] - Adjusted EBITDA is expected to be at least $1515 billion[7] - Adjusted EPS is projected to be at least $11.75[7] - Free cash flow is anticipated to be at least $1145 billion[7]
Cabot (CBT) - 2025 Q3 - Earnings Call Presentation
2025-08-05 12:00
Financial Performance - Diluted EPS was $1.86, while adjusted EPS was $1.90, a decrease of 1% year-over-year[5] - Performance Chemicals segment EBIT reached $57 million, showing a 4% increase year-over-year[5] - Reinforcement Materials segment EBIT amounted to $128 million, a decrease of 6% year-over-year[5] - The company returned $64 million to shareholders through dividends and share repurchases[5] - Cash flow from operations was $249 million, with free cash flow of $188 million[22] - The company expects capital expenditures for fiscal year 2025 to be in the range of $250 million to $275 million[22] Strategic Initiatives - An agreement was announced to acquire Bridgestone's reinforcing carbons plant in Mexico for $70 million[7, 11] - Cabot was awarded a platinum rating from EcoVadis for exceptional sustainability performance for the fifth consecutive year, ranking in the top 1% of companies assessed by EcoVadis globally[8, 14] - Notable growth was achieved in Battery Materials, with a 20% contribution margin improvement driven by differentiated products[7, 15] Outlook - The company reaffirms its adjusted EPS guidance range of $7.15 to $7.50 for fiscal year 2025[38, 41, 46]
Embraer(ERJ) - 2025 Q2 - Earnings Call Presentation
2025-08-05 12:00
Financial Highlights - All-time high 2Q revenue of $1.8 billion[6] - Highest 2Q Adjusted EBIT margin of +10.5% over the last 10 years[6] - Backlog reached a new record of $29.7 billion[6] - Adjusted Net Results excludes Eve is -$5 million[49] - Shareholder remuneration: Dividends of R$51.4 million and Interest on Equity of R$142.8 million[53] Operational Performance - 2Q deliveries were 30% higher year-over-year[6] - Book-to-bill ratio is around 2x across all business units[6] - Commercial Aviation revenue increased by 4% year-over-year with an EBIT of $25 million[18] - Executive Aviation revenue increased significantly by 64% year-over-year with an EBIT of $80 million[21] - Defense & Security revenue increased by 18% year-over-year with an EBIT of $20 million[25] - Services & Support revenue increased by 13% year-over-year with an EBIT of $71 million[27] Strategic Developments - SAS ordered 45 E195-E2 aircraft, with 10 optional units[7] - SkyWest purchased 60 E175 aircraft, with 50 additional options[7] - Portugal made its 6th KC-390 purchase, along with 10 new options, and Lithuania selected the KC-390[7] US Market Focus - Embraer forecasts $21 billion in US imports and $13 billion in exports by 2030, resulting in an $8 billion trade surplus for the US[15]
Henry Schein(HSIC) - 2025 Q2 - Earnings Call Presentation
2025-08-05 12:00
Financial Performance - Q2 2025 - Total sales increased by 3.3% to $3.24 billion[18, 54], with constant currency growth of 2.7%[15, 19, 22] - Non-GAAP diluted EPS was $1.10, a decrease of 10.6% compared to $1.23 in Q2 2024[15, 18, 54] - Adjusted EBITDA was $256 million, a decrease of 4.8% compared to $268 million in Q2 2024[15, 18, 57] - Global Distribution and Value-Added Services Group sales grew by 2.4% in constant currency[15, 22] - Global Specialty Products Group sales grew by 3.3%[15, 22] - Global Technology Group sales grew by 6.6%[15, 22] Segment Performance - U S dental merchandise sales decreased 1.2%[22] - International dental merchandise constant currency sales grew 0.5%[22] - U S Medical sales grew 6.3% including acquisitions[22] Guidance and Strategy - The company maintains 2025 non-GAAP diluted EPS guidance of $4.80 to $4.94[12, 46, 48] - 2025 Adjusted EBITDA is expected to grow in the mid-single digits versus 2024 Adjusted EBITDA of $1.1 billion[46] - Total sales growth for 2025 is projected to be between 2% and 4%[12, 48]